Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus METOPROLOL SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus METOPROLOL SUCCINATE.
BETAPACE vs METOPROLOL SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors. Also suppresses renin release.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
25 to 100 mg orally once daily, titrated at weekly intervals as tolerated; maximum 400 mg/day
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 3-7 hours. Twice-daily dosing (metoprolol succinate) provides stable beta-blockade over 24 hours due to extended-release formulation, not due to half-life.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Primarily renal (95% as metabolites, <5% unchanged). Three main metabolites: O-demethylated (active), α-hydroxylated (active), and O-demethylated and α-hydroxylated. Biliary/fecal excretion: <5%.
Category C
Category C
Beta-Blocker
Beta-Blocker